Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

Rhea-AI Summary

Foghorn Therapeutics (NASDAQ: FHTX), a clinical-stage biotech company focused on developing medicines that correct abnormal gene expression, announced its participation in the upcoming Citizens Life Sciences Conference in New York on May 7-8, 2025. CEO Adrian Gottschalk will present in a fireside chat on May 7 at 9:30 a.m. EST and participate in one-on-one meetings throughout the day. The company's Gene Traffic Control® platform primarily targets oncology applications and aims to develop treatments for a broad spectrum of diseases.

News Market Reaction – FHTX

-8.49%

-8.49% Session move

In the trading session that priced this news, FHTX declined 8.49%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Citizens Life Sciences Conference, being held May 7-8, 2025, in New York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Fireside Chat Data and Time: Wednesday, May 7, 2025, at 9:30 a.m. EST
Presenter: Adrian Gottschalk, President and Chief Executive Officer

Management will also participate in one-on-one meetings on Wednesday, May 7, 2025.

About Foghorn Therapeutics
Foghorn^® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control^® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn.

Contact:
Karin Hellsvik, Foghorn Therapeutics Inc. khellsvik@foghorntx.com 

FAQ

When is Foghorn Therapeutics (FHTX) presenting at the Citizens Life Sciences Conference 2025?

Foghorn Therapeutics will present at the Citizens Life Sciences Conference on Wednesday, May 7, 2025, at 9:30 a.m. EST in New York.

Who will represent Foghorn Therapeutics (FHTX) at the Citizens Life Sciences Conference 2025?

Adrian Gottschalk, President and Chief Executive Officer of Foghorn Therapeutics, will represent the company at the conference.

What is Foghorn Therapeutics' (FHTX) main technology platform?

Foghorn Therapeutics utilizes its Gene Traffic Control® platform to develop medicines that treat serious diseases by correcting abnormal gene expression.

What is the primary therapeutic focus of Foghorn Therapeutics (FHTX)?

Foghorn Therapeutics' primary therapeutic focus is in oncology, with potential applications across a wide spectrum of diseases.